{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T22:08:05Z","timestamp":1768255685346,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,10,1]],"date-time":"2007-10-01T00:00:00Z","timestamp":1191196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2007,10]]},"DOI":"10.1016\/j.jhep.2007.03.028","type":"journal-article","created":{"date-parts":[[2007,6,22]],"date-time":"2007-06-22T11:22:43Z","timestamp":1182511363000},"page":"476-483","source":"Crossref","is-referenced-by-count":23,"title":["Phase 2 study of the combination of merimepodib with peginterferon-\u03b12b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C"],"prefix":"10.1016","volume":"47","author":[{"given":"Patrick","family":"Marcellin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Horsmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Didier","family":"Grange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Bronowicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Vetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Purdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leif","family":"Bengtsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay","family":"McNair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Alam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2007.03.028_bib1","first-page":"S3","article-title":"Management of hepatitis C","volume":"36","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.03.028_bib2","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1002\/hep.1840360706","article-title":"Natural history of chronic hepatitis C","volume":"36","author":"Seeff","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.03.028_bib3","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1002\/hep.1840360707","article-title":"Fibrosis and disease progression in hepatitis C","volume":"36","author":"Marcellin","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2007.03.028_bib4","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM199506013322202","article-title":"Clinical outcomes after transfusion-associated hepatitis C","volume":"332","author":"Tong","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2007.03.028_bib5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/hep.20119","article-title":"Diagnosis, management and treatment of hepatitis C","volume":"39","author":"Strader","year":"2004","journal-title":"AASLD Pract Guidel Hepatol"},{"key":"10.1016\/j.jhep.2007.03.028_bib6","unstructured":"Pegasys\u00ae, peginterferon alfa 2a. Complete Product Information, <http:\/\/www.rocheusa.com>; 2004 [accessed 19.11.04]."},{"key":"10.1016\/j.jhep.2007.03.028_bib7","unstructured":"Peg-Intron\u00ae powder for injection. Complete Prescribing Information, <http:\/\/www.spfiles.com>; 2004 [accessed 19.11.04]."},{"key":"10.1016\/j.jhep.2007.03.028_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-\u03b12a and ribavirin combination therapy in chronic hepatitis c: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"Hadziyannis","year":"2004","journal-title":"Ann Int Med"},{"key":"10.1016\/j.jhep.2007.03.028_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis c infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Eng J Med"},{"key":"10.1016\/j.jhep.2007.03.028_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2007.03.028_bib11","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1126\/science.285.5424.110","article-title":"Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line","volume":"285","author":"Lohmann","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jhep.2007.03.028_bib12","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1126\/science.290.5498.1972","article-title":"Efficient initiation of HCV RNA replication in cell culture","volume":"290","author":"Blight","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.jhep.2007.03.028_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1046\/j.1365-2125.1998.00836.x","article-title":"Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions","volume":"46","author":"Khakoo","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jhep.2007.03.028_bib14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-123-12-199512150-00001","article-title":"Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial","volume":"123","author":"Di Bisceglie","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2007.03.028_bib15","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/0140-6736(91)91707-2","article-title":"Ribavirin treatment for chronic hepatitis C","volume":"337","author":"Reichard","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2007.03.028_bib16","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/135965350501000503","article-title":"A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon alfa in previously untreated patients with chronic hepatitis C","volume":"10","author":"McHutchison","year":"2005","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2007.03.028_bib17","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.gtc.2004.04.004","article-title":"Treatment of relapsers after combination therapy for chronic hepatitis C","volume":"33","author":"Ahmed","year":"2004","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jhep.2007.03.028_bib18","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1053\/j.gastro.2004.01.014","article-title":"Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment","volume":"126","author":"Shiffman","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2007.03.028_bib19","first-page":"40","volume":"42","author":"Poynard","year":"2005","journal-title":"Abstr J Hepatol"},{"key":"10.1016\/j.jhep.2007.03.028_bib20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0042-6822(03)00152-1","article-title":"The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA","volume":"310","author":"Zhou","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2007.03.028_bib21","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modeling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"Dixit","year":"2004","journal-title":"Nature"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827807003455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827807003455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T06:31:09Z","timestamp":1707978669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827807003455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["S0168827807003455"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2007.03.028","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2007,10]]}}}